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Abstract Data concerning the benefits and risks of pri-
mary PCI in the elderly patients presenting with ST-segment
elevation myocardial infarction (STEMI) are limited. Thus,
the objective of the study was to assess age-dependent
differences in the treatment and outcomes of STEMI
patients transferred for primary PCI. Data were gathered on
1,650 consecutive STEMI patients from hospital networks
in seven countries of Europe from November 2005 to
January 2007 (the EUROTRANSFER Registry popula-
tion). Patients \65, 65 to 74, 75 to 84, and C85 years of
age comprised 49.3, 27.5, 20.2, and 3 % of the registry
population, respectively. Elderly patients were higher risk
individuals and have experienced longer delays to reper-
fusion than their younger counterparts and were more
likely to be treated conservatively after coronary angiog-
raphy. Despite similar frequency of TIMI 3 flow before
PCI, elderly patients were less likely to achieve TIMI 3
flow and ST-segment resolution[50 % after PCI, and were
more likely to have PCI complications. The rates of death
at 30 days, as well as at 1 year were increased with age. In
the Cox regression analysis model age was an independent
predictor of 30-day mortality. A trend toward higher risk of
major bleeding requiring transfusion was observed. Age
was an important determinant of treatment strategies
selection and clinical outcomes in the group of consecutive
STEMI patients transferred for primary PCI. Further efforts
should be made to reduce delays and to optimize treatment
of STEMI, regardless of patients’ age.
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Background
Elderly patients presenting with ST-segment elevation
myocardial infarction (STEMI) are less likely to receive
reperfusion therapies, both fibrynolysis and primary per-
cutaneous coronary intervention (PCI) [1–3]. Common
reasons for excluding older patients from reperfusion
therapy are their delayed presentation and atypical symp-
toms. Also, up to 9 % of elderly patients have absolute
contraindication to fibrynolytic therapy [4]. Nowadays,
primary PCI is the preferred method of reperfusion for
STEMI, also in elderly patients [5]. It has been shown to be
more effective than fibrynolysis in reduction of ischemic
events in patients C75 years old with STEMI with chest
pain \6 h [6]. However, primary PCI carries a decreased
success rate and an increased procedural risk in older
patients when compared with younger ones. Elderly
STEMI patients are also at the higher risk of death or other
adverse ischemic and non-ischemic events as result of
higher prevalence of comorbidities.
Elderly patients with STEMI are often excluded from
randomized clinical trials, thus it is hard to generalize
expected outcomes from randomized clinical trials to the
real life setting. More reliable data on treatment and out-
comes of elderly patients with STEMI can be extracted
from multicenter registries. The objective of the present
study was to assess whether there exist age-dependent
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differences in the clinical characteristics, treatment strate-
gies and clinical outcomes in patients with STEMI trans-
ferred for primary PCI based on data from the European
Registry on Patients with ST-Elevation MI Transferred for
Mechanical Reperfusion with a Special Focus on Upstream
Use of Abciximab (EUROTRANSFER) Registry [7–9].
Methods
The details of the EUROTRANSFER Registry (Clinical-
Trials.gov number NCT00378391) protocol and main
results have been previously published [7–9]. In this reg-
istry data concerning treatment and outcomes of 1,650
consecutive, transferred STEMI patients in 15 STEMI
hospital networks from 7 European countries between
November 2005 and January 2007 were collected. For the
purpose of this analysis patients were divided into four age
groups (\65, 65–74, 75–84 and C85 years of age). The
study protocol and execution complied with the Declara-
tion of Helsinki and has been approved by the Institutional
Review Board.
All-cause death, reinfarction and urgent revasculariza-
tion (PCI or coronary artery bypass grafting) and bleeding
complications: puncture site hematoma, intracranial hem-
orrhage, major bleeding requiring transfusion were evalu-
ated during 30-day follow-up [7]. Additionally 1-year
mortality was assessed [8]. Data concerning Thrombolysis
In Myocardial Infarction (TIMI) flow in the infarct-related
artery before and after PCI, ST-segment resolution after
PCI, and rate of PCI complications (no-reflow, distal
embolization, side branch occlusion, artery perforation)
were also provided.
Data were analyzed according to the established stan-
dards of descriptive statistics. Results were presented as
percentages of patients or medians (inter-quartile range).
Differences in dichotomous variables were analyzed using
Chi-square test and the Fisher’s exact test as appropriate.
Continuous variables were compared by the Kruskal–
Wallis test. The difference in death rates between groups
during follow-up period was assessed by the Kaplan–Meier
method using the log-rank test. In addition, multivariate
Cox regression analysis was performed to find significant
predictors of 30-day death. Risk of 30-day death was
expressed as hazard ratios with 95% confidence intervals.
All tests were two-tailed and a p value of \0.05 was
considered statistically significant. All statistical analysis
was performed using SPSS 15.0 (SPSS Inc., Chicago, IL).
Results
Data on 1,650 patients were entered into the EURO-
TRANSFER Registry database. Patients \65, 65–74,
75–84, and C85 years of age comprised 49.3, 27.5, 20.2,
and 3.0 % of the registry population, respectively. Char-
acteristics of patient population according to age are shown
in Table 1. The prevalence of female gender, diabetes
mellitus, previous myocardial infarction, previous heart
failure symptoms, previous stroke, current smoking and
chronic kidney disease, as well as body mass index and
diastolic blood pressure changed across age groups.
Table 1 Baseline demographics and clinical status on admission to percutaneous coronary intervention center stratified by age
Variable Age (years) p value
\65 (n = 814) 65–75 (n = 454) 75–85 (n = 333) C85 (n = 49)
Male 82.1 70.3 54.7 40.8 \0.0001
Body mass index (kg/m2) 26.9 (24.4–29.9) 27.1 (24.8–29.7) 25.7 (23.5–28.4) 24.1 (22.4–26.7) \0.0001
Diabetes mellitus 11.9 18.7 21.9 14.3 \0.0001
Previous myocardial infarction 8.6 16.1 16.8 18.4 \0.0001
Previous heart failure symptoms 0.4 1.8 3.3 0 0.001
Previous percutaneous coronary intervention 6.9 7 9 6.1 0.65
Previous coronary artery bypass grafting 0.9 2.4 0.9 2 0.094
Previous stroke 2.2 4.8 4.2 8.2 0.013
Current smoker 55 22.9 12.9 2 \0.0001
Peripheral arterial disease 2.7 3.5 3 10.2 0.064
Chronic kidney disease 1.0 2.9 3.9 4.1 0.004
Heart rate on admission (beat/min) 78 (68–88) 78 (68–90) 76 (65–88) 75 (65–90) 0.50
Systolic blood pressure on admission (mmHg) 130 (150–120) 126 (117–156) 135 (115–152) 134 (116–166) 0.58
Diastolic blood pressure on admission (mmHg) 80 (70–91) 80 (70–90) 75 (65–85) 80 (64–90) \0.0001
Killip IV on admission 2.7 3.3 3.3 6.1 0.78
Values are presented as percentages or medians (inter-quartile range)
Age-related differences in treatment strategies 215
123
Data concerning pharmacological and interventional
treatment are summarized in Table 2. Elderly patients has
experienced longer delays to individual stages of treatment
than their younger counterparts (Table 2) and they were
less likely to be treated with diagnosis-to-balloon time
\90 min (for age\65, 65–74, 75–84, and C85 percentage
of patients with diagnosis-to-balloon time\90 min was as
follows: 40.8, 34.1, 35.1, 34.7 %, p = 0.079). There was
no difference in the frequency of unfractionated heparin
and abciximab use across age groups, both in pre-cathlab
and in the cathlab setting. However, a trend toward less
frequent administration of clopidogrel in older patients was
observed (Table 2).
In the coronary angiography prevalence of multivessel
disease increased with age. A total of 1,537 patients (93.2
% of study population) underwent immediate PCI. Elderly
patients were more likely to be treated conservatively after
coronary angiography and were less likely to receive stents,
especially drug-eluting stents during immediate PCI
(Table 2). TIMI grade 3 flow frequency before PCI was
similar among age groups, but elderly patients were less
likely to achieve optimal epicardial flow (TIMI grade 3
flow) after PCI, and were more likely to have PCI com-
plications than their younger counterparts (Fig. 1; Table 2).
Similarly, rate of ST-segment resolution [50 % after PCI
has shown age-dependency.
Table 2 Concomitant medications, timing information and invasive treatment details stratified by age
Variable Age (years) p Value
\65 (n = 814) 65–75 (n = 454) 75–85 (n = 333) C85 (n = 49)
Pain-to-diagnosis time (min) 96 (52–198) 111 (60–213) 132 (68–240) 97 (47–303) \0.0001
Diagnosis-to-balloon time (min) 100 (77–138) 109 (83–155) 109 (80–145) 110 (67–154) 0.010
Admission to cathlab-to-balloon time (min) 30 (20–41) 31 (21–45) 32 (23–44) 33 (20–47) 0.11
Pain-to-balloon time (min) 216 (150–329) 240 (165–377) 251 (168–379) 200 (155–425) \0.0001
Clopidogrel pre-cathlab 33.7 32.8 28.8 22.4 0.19
Clopidogrel in the cathlab 46.7 46.9 48.3 36.7 0.38
Unfractionated heparin pre-cathlab 68.2 67.2 69.4 69.4 0.93
Unfractionated heparin in the cathlab 61.3 63.7 61.9 51 0.37
Abciximab pre-cathlab 43.5 46.9 42.9 34.7 0.12
Abciximab in the cathlab 23.5 21.2 17.7 26.5
No abciximab 33 31.9 39.4 38.8
Femoral access 86.4 84.4 88.3 87.8 0.45
IRA in baseline angiography
LMCA 1.2 0.2 0.6 2 0.15
LAD 42.1 45.2 48 46.9 0.30
LCX 13.3 11.9 11.1 10.2 0.71
RCA 42.4 40.1 38.1 40.8 0.59
Multi-vessel disease 42.5 55.1 64.3 75.5 \0.0001
Abandoned PCI 5.7 5.5 10.2 16.3 0.002
Immediate PCI 94.3 94.5 89.8 83.7
Number of patients undergoing immediate PCI (n) 768 429 299 41
Stent 94.8 93.5 88.6 82.9 0.001
Drug-eluting stent 27.9 24.5 19.7 9.8 0.005
[1 stent in IRA 21 20.4 23.4 26.5 0.85
Thrombectomy 12.2 11.7 10.4 12.2 0.86
Non-IRA PCI 4 5.4 5.7 4.9 0.55
PCI complications (no-reflow, distal embolization,
side branch occlusion, artery perforation)
7.3 9.3 14.4 14.6 0.003
Intra-aortic balloon pumping 3.4 4.7 4.3 2.4 0.69
Values are presented as percentages or medians (inter-quartile range)
IRA infarct-related artery, LAD left anterior descending, LCX circumflex artery, LMCA left main coronary artery, PCI percutaneous coronary
intervention, RCA right coronary artery
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As shown in Fig. 2a, the rates of death, death ? rein-
farction and all major adverse cardiovascular events at
30 days were increased with age. In contrast, incidences
of reinfarction and urgent revascularization at 30 days
were independent of age. The Kaplan–Meier curves for
survival according to age are shown in Fig. 3. In Cox
regression analysis, independent predictors of 30-day
death were: age, diabetes mellitus, previous stroke, heart
rate on admission, systolic blood pressure on admission,
cardiogenic shock (Killip IV) on admission, diagnosis-
to-balloon time, stent implantation during PCI, drug-eluting
stent implantation during PCI, non-infarct-related artery
PCI, left anterior descending artery as infarct-related
artery, TIMI grade 3 flow after PCI, ST-segment resolu-
tion [50 % after PCI and major bleeding requiring
transfusion (Table 3).
Fig. 2 Ischemic events a (death, death ? reinfarction, death ? rein-
farction ? revascularization) and bleeding events b (puncture site
hematoma, intracranial hemorrhage, major bleeding requiring
transfusion, total bleeding events) at 30-day follow-up stratified by
age. ReMI reinfarction
Fig. 1 Thrombolysis in myocardial infarction flow before and after
PCI, and ST-segment resolution [50 % frequency in 1,537 patients
undergoing immediate percutaneous coronary intervention stratified
by age. PCI percutaneous coronary intervention, STR ST-segment
resolution, TIMI Thrombolysis in myocardial infarction
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As clearly shown in Fig. 2b there were no differences in
the occurrence of puncture site hematoma and intracranial
hemorrhage (which did not occur in either group) across
age groups. A trend toward higher risk of major bleeding
requiring transfusion and significantly higher incidence of
all bleeding complications in elderly patients (especially
C85 years of age) were observed.
Discussion
Our study suggests that age is still an important determi-
nant of treatment strategies selection, even in well-organized
networks of STEMI treatment. Elderly patients are treated
less aggressively in terms of antiplatelet therapy, have
experienced longer delays to successful reperfusion, and
they are at higher risk of death during follow-up.
In our study, similar to previous studies, and as expec-
ted, higher mortality rate was observed in older patients.
There are many reasons that contribute to this higher
mortality. One of potential explanations of the short- and
long-term clinical outcome worsening in elderly STEMI
patients is higher prevalence of comorbidities. In line with
previous studies, elderly patients were more likely to have
diabetes mellitus, previous myocardial infarction, previous
heart failure symptoms, previous stroke, and chronic
kidney disease [1, 10–14]. Older patients experienced
longer time-delays to admission and primary PCI, and
presenting more frequently with acute heart failure symp-
toms. Importantly, ischemia time is a major determinant of
survival in patients with STEMI. Another important risk
factor for higher mortality in patients with acute coronary
syndromes is the presence of renal function impairment
[15, 16]. Preexisting impairment of renal function, diabetes
mellitus and advanced age are also associated with
increased risk of contrast induced nephropathy develop-
ment after coronary angiography and primary PCI, which
may led to worsening of long-term prognosis [17, 18].
Elderly patients are also at higher risk of non-cardiac death
during follow-up related to cancer or lung diseases. Simi-
larly, to previous reports in our study observed frequency
of reinfarction and need of repeated revascularization was
comparable across age groups [1, 10].
It is well established that in elderly patients primary PCI
success rate is lower, with higher risk of angiographic
complications than in younger counterparts [12–14]. In our
study, the frequency of optimal epicardial flow (TIMI
grade 3 flow) after primary PCI decreases with age. In
Fig. 3 One-year Kaplan–Meier survival curves stratified by age
Table 3 Multivariate Cox
regression analysis for 30-day
death
Values are presented as hazard
ratios with 95% confidence
intervals
IRA infarct-related artery, LAD
left anterior descending, PCI
percutaneous coronary
intervention, TIMI
Thrombolysis in myocardial
infarction
Variable Hazard ratio 95% Confidence
interval
p Value
Age (per 1 year) 1.049 1.026–1.072 \0.0001
Diabetes mellitus 1.879 1.074–3.288 0.027
Previous stroke 3.118 1.311–7.416 0.010
Heart rate on admission (per 1 beat/min) 1.025 1.013–1.038 \0.0001
Systolic blood pressure on admission (per 1 mmHg) 0.983 0.973–0.993 0.001
Killip IV on admission 2.681 1.347–5.337 0.005
Diagnosis to balloon time (per 1 min) 0.995 0.990–1.000 0.035
IRA LAD 1.971 1.142–3.399 0.015
Stent implantation during PCI 0.369 0.197–0.689 0.002
Drug-eluting stent implantation during PCI 0.401 0.175–0.918 0.031
Non-IRA PCI 3.055 1.402–6.657 0.005
TIMI grade 3 flow after PCI 0.396 0.221–0.709 0.002
ST-segment resolution [50% after PCI 0.352 0.205–0.602 \0.0001
Major bleeding requiring transfusion 3.057 1.056–8.845 0.039
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contrast, in the Controlled Abciximab and Device Inves-
tigation to Lower Late Angioplasty Complications
(CADILLAC) Trial correlation between final epicardial
flow after PCI and age was not observed [10]. The complex
coronary anatomy observed in elderly patients may be
associated with a higher incidence of distal embolization,
which is a important determinant of myocardial perfusion
after primary PCI, as well as long-term clinical outcome
[13, 14, 19]. In addition, De Luca et al. have found a
relationship between increased age and impaired myocar-
dial perfusion assessed by myocardial blush grade, and
ST-segment resolution. Importantly, age and poor myo-
cardial perfusion were independently associated with
1-year mortality [12]. The higher prevalence of multi-
vessel disease and the fear of complications among elderly
may account for more frequent selection of initial conser-
vative approach, with postponed PCI or coronary artery
bypass grafting. Presence of multi-vessel disease in STEMI
patients influences the clinical outcomes of patients treated
with primary PCI [20]. Also, as confirmed by our study
patients with advanced age are less likely to be treated with
drug-eluting stents in STEMI setting [21].
In the analyzed patients population there was a trend
toward higher rate of major bleeding requiring transfusion
in patients with advanced age [10]. Importantly, major
bleeding occurrence is a strong predictor of short- and long-
term mortality [22–26]. Also, major bleeding may be
associated with higher incidence of ischemic events, for
example myocardial infarction, unplanned ischemic revas-
cularization, and stent thrombosis [22]. An increased like-
lihood of the vascular access site complications (hematomas
or aneurysm) in elderly patients is a result of the presence of
calcified, fragile and bleeding prone vessels in these
patients. In addition, in elderly patients frequently reduced
kidney function is leading to overdosing of antithrombotic
drugs, and to the increased risk of bleeding. Access site
bleeding complications could be decreased by broad usage
of radial approach, which was used in\15 % of patients in
the EUROTRANSFER registry [27]. Safety and efficacy of
transradial catheterization in the elderly is similar to
observed in younger patients. Importantly, it may improve
the comfort of the patients, especially in the context of the
age-related diseases that frequently affect elderly patients
[28]. However, advanced age was identified as an inde-
pendent predictor of selection femoral over radial access by
the operator during primary PCI in our registry [27]. Also, a
fear of bleeding may limit the use of antiplatelet agents,
especially glycoprotein IIb–IIIa inhibitors in patients
C75 years of age [29]. Importantly, previous studies have
shown that patients who present with an acute coronary
syndrome and do not receive guideline-recommended
therapies, including glycoprotein IIb–IIIa inhibitors expe-
rienced higher short- and long-term mortality [30–32].
Limitations of the study
The present study has a number of limitations. First, the
study group is relatively small, and the very eldery patient
subset (C85 years of age) comprised only 3 % of the study
population. Also, the study focused mainly on 30-day
clinical outcomes. Secondly, patients were not screened for
contraindications to use of each medication and appropri-
ateness of used dosage was not assessed. It is very likely
that in some of patients various therapies were not used due
to an important clinical reason. The registry was conducted
between November 2005 and January 2007 when new
P2Y12 inhibitors (prasugrel, ticagrelor) were not available.
Also, the frequency of bivalirudin monotherapy was rather
low, as it was recommended as alternative to unfraction-
ated heparin and glycoprotein IIb–IIIa inhibitors combi-
nation recently [5]. Thus, the study did not cover most
contemporary pharmacological treatment patterns for
STEMI. On the other hand, since year 2007 there was no
significant change in the recommendations concerning the
application of primary PCI in STEMI setting [5]. Finally,
the interpretation of the TIMI flow grade measurements, as
well as ST-resolution was limited by the fact that these
represent not independent core-lab, but physician’s
assessments.
Conclusions
Age was an important determinant of treatment strategies
selection and clinical outcomes in the group of consecutive
STEMI patients transferred for primary PCI. Further efforts
should be made to reduce delays and to optimize treatment
of STEMI, regardless of patients’ age.
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